Is Nuvation Bio Inc. (NUVB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.6% / 30% | 31.9% / 30% | 1.0% / 30% | 343.73% / 5% | ✗ NOT HALAL |
| DJIM | 0.6% / 33% | 31.9% / 33% | 1.0% / 33% | 343.73% / 5% | ✗ NOT HALAL |
| MSCI | 1.6% / 33% | 93.0% / 33% | 3.0% / 33% | 343.73% / 5% | ✗ NOT HALAL |
| S&P | 0.6% / 33% | 31.9% / 33% | 1.0% / 33% | 343.73% / 5% | ✗ NOT HALAL |
| FTSE | 1.6% / 33% | 93.0% / 33% | 3.0% / 50% | 343.73% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 85.2% | |
| Operating Margin | -81.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -53.2% | |
| Return on Assets (ROA) | -23.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$173M |
| Free Cash Flow | -$182M |
| Total Debt | $57M |
| Debt-to-Equity | 21.9 |
| Current Ratio | 7.0 |
| Total Assets | $595M |
Price & Trading
| Last Close | $4.42 |
| 50-Day MA | $5.22 |
| 200-Day MA | $4.64 |
| Avg Volume | 5.5M |
| Beta | 1.5 |
|
52-Week Range
$1.54
| |
About Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Nuvation Bio Inc. (NUVB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Nuvation Bio Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Nuvation Bio Inc.'s debt ratio?
Nuvation Bio Inc.'s debt ratio is 0.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.6%.
What are Nuvation Bio Inc.'s key financial metrics?
Nuvation Bio Inc. has a market capitalization of $1.5B, and revenue of $63M. Return on equity stands at -53.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.